Difficulty: Medium
Average Score: 75%
Practice
A nurse is caring for a woman with breast cancer who is receiving tamoxifen. A review of this patientÔÇÖs chart reveals a deficiency of the CYP2D6 gene. The nurse will contact the provider to suggest:
Correct answer
A
Rationale
In this scenario, the correct answer is A) a different medication. Tamoxifen is a prodrug that requires activation by the CYP2D6 enzyme to its active form. Patients with a deficiency in the CYP2D6 gene may not be able to metabolize tamoxifen effectively, leading to reduced therapeutic effects. Therefore, suggesting a different medication that does not rely on CYP2D6 for activation is the appropriate course of action.
Option B) an increased dose is not the correct choice because simply increasing the dose would not address the underlying issue of the patient's inability to metabolize tamoxifen efficiently. This could potentially lead to increased side effects without improving efficacy.
Option C) a reduced dose is also not a suitable option as lowering the dose would further compromise the already limited effectiveness of tamoxifen in patients with a CYP2D6 deficiency.
Option D) serum drug levels would not provide a solution to the problem at hand. Monitoring drug levels would not change the fact that the patient is unable to metabolize tamoxifen effectively due to the genetic deficiency.
Educationally, understanding the pharmacogenetics of drug metabolism is crucial in individualizing patient care and optimizing treatment outcomes. Nurses need to be aware of how genetic variations can impact drug responses and advocate for appropriate medication adjustments based on these variations to ensure safe and effective therapy for their patients.
Option B) an increased dose is not the correct choice because simply increasing the dose would not address the underlying issue of the patient's inability to metabolize tamoxifen efficiently. This could potentially lead to increased side effects without improving efficacy.
Option C) a reduced dose is also not a suitable option as lowering the dose would further compromise the already limited effectiveness of tamoxifen in patients with a CYP2D6 deficiency.
Option D) serum drug levels would not provide a solution to the problem at hand. Monitoring drug levels would not change the fact that the patient is unable to metabolize tamoxifen effectively due to the genetic deficiency.
Educationally, understanding the pharmacogenetics of drug metabolism is crucial in individualizing patient care and optimizing treatment outcomes. Nurses need to be aware of how genetic variations can impact drug responses and advocate for appropriate medication adjustments based on these variations to ensure safe and effective therapy for their patients.